PROCEPT BioRobotics AI Stock Analysis
Want to see PRCT full AI Analyst Report?
PROCEPT BioRobotics (PRCT) AI Stock Analysis
PROCEPT BioRobotics
(NASDAQ:PRCT)
The score is driven primarily by strong growth and improving gross margins, but capped by ongoing losses and heavy negative free cash flow. Technicals are supportive (price above key moving averages with positive MACD). Earnings call guidance was constructive (raised/maintained growth outlook and expected Q4 positive adjusted EBITDA), while valuation remains constrained due to negative earnings and no dividend support.
PROCEPT BioRobotics Key Performance Indicators (KPIs)
Revenue by SegmentSeparates income from capital device sales, consumable disposables, and recurring services or training, showing how much revenue is one-time versus repeatable. A higher share of consumables and service revenue points to more predictable, annuity-like cash flow from the installed base, while heavy reliance on device sales makes results more dependent on hospital budgets and adoption cycles.
Consumables (handpieces) have become the revenue engine—now the largest, recurring, and fastest-growing line, reflecting accelerating procedures and strong customer stickiness—critical for predictable lifetime revenue. System sales remain lumpy but rising ASPs show pricing power and uptake among larger accounts; however system variability plus management’s commercial realignment and higher tariffs create back‑loaded benefits and margin risk. Watch Q2 procedure momentum, the handpiece:procedure ratio and sustained system ASPs—those will determine whether gross‑margin targets and the promised Q4 EBITDA inflection are achievable.
The FlyPROCEPT BioRobotics (PRCT) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $1.35B
- Dividend Yield
- ―
- Average Volume (3M)
- 1.25M
- Price to Earnings (P/E)
- -11.5
- Beta (1Y)
- 0.70
- Revenue Growth
- 17.47%
- EPS Growth
- -31.69%
- Country
- US
- Employees
- 888
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
PROCEPT BioRobotics Business Overview & Revenue Model
Company Description
PROCEPT BioRobotics Corporation specializes in pioneering surgical robotic technologies, offering innovative solutions within the field of urology. Its flagship product is the AquaBeam Robotic System, a sophisticated, image-guided surgical robot desi...
PROCEPT BioRobotics Earnings Call Summary
The call was predominantly positive. Revenue, procedures, international sales, HYDROS utilization, pricing, replacement activity, clinical progress and full-year guidance were strong, while management emphasized continued commercial execution and an expected return to positive adjusted EBITDA in Q4. The main challenges were flat U.S. system revenue, lower legacy AQUABEAM utilization, a required Q4 procedure acceleration, higher operating expenses and larger year-over-year losses.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
For 2026, PROCEPT expects total revenue of $390 million to $410 million, representing growth of approximately 27% to 33%, international revenue of $50 million to $51 million, around 54,000 procedures, consistent with guidance of 54,000 to 56,000 procedures, and 50 to 60 replacement sales at an average selling price of approximately $315,000; new U.S. system average selling prices are expected to remain relatively consistent with $495,000, fourth quarter gross margins are expected to be approximately 65%, operating expenses are expected to be in the range of $359 million to $363 million, and adjusted EBITDA loss is expected to be in the range of $35 million to $30 million, implying positive adjusted EBITDA in the fourth quarter, with Q4 guidance implying positive $3 million to positive $9 million. For 2027, approximately 20% year-over-year revenue growth is a starting point for planning, with capital probably being similar to 2026, pricing relatively stable, international growth fairly comparable to 2026 and somewhere around the 25% to 30% range, again, perhaps as low as 20%, and 100 to 200 basis point expansion on a yearly basis a reasonable place to be for gross margin.
PROCEPT BioRobotics Financial Statement Overview
Summary
Very strong revenue scaling and improving gross margin (~64.7% TTM) are positives, supported by modest leverage (debt ~0.16x equity). However, the company remains meaningfully unprofitable (TTM net margin ~-32.6%) with significant cash burn (TTM operating cash flow about -$114.8M; free cash flow about -$126.1M), keeping funding/execution risk elevated.
Income Statement
58NeutralBalance Sheet
66PositiveCash Flow
42Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 352.30M | 308.05M | 224.50M | 136.19M | 75.01M | 34.47M |
| Gross Profit | 227.79M | 196.23M | 137.10M | 71.05M | 37.09M | 15.87M |
| EBITDA | -103.25M | -85.41M | -82.00M | -98.09M | -79.13M | -50.72M |
| Net Income | -114.86M | -95.57M | -91.41M | -105.90M | -87.15M | -59.85M |
Balance Sheet | ||||||
| Total Assets | 473.76M | 508.08M | 534.02M | 404.72M | 309.33M | 337.02M |
| Cash, Cash Equivalents and Short-Term Investments | 218.37M | 286.50M | 333.73M | 257.22M | 222.64M | 304.32M |
| Total Debt | 76.99M | 78.48M | 80.25M | 79.20M | 77.32M | 54.10M |
| Total Liabilities | 144.85M | 142.21M | 131.80M | 123.97M | 112.26M | 69.93M |
| Stockholders Equity | 328.91M | 365.87M | 402.22M | 280.75M | 197.07M | 267.09M |
Cash Flow | ||||||
| Free Cash Flow | -126.11M | -58.34M | -103.62M | -133.21M | -83.03M | -57.93M |
| Operating Cash Flow | -114.82M | -48.98M | -99.21M | -108.00M | -80.38M | -57.33M |
| Investing Cash Flow | -11.30M | -9.36M | -4.41M | -25.21M | -2.65M | -592.00K |
| Financing Cash Flow | 9.48M | 11.19M | 180.13M | 167.79M | 3.61M | 262.12M |
PROCEPT BioRobotics Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRCT, the sentiment is Positive. The current price of 23.51 is above the 20-day moving average (MA) of 20.33, above the 50-day MA of 19.47, and above the 200-day MA of 22.93, indicating a bullish trend. The MACD of 1.06 indicates Negative momentum. The RSI at 67.98 is Neutral, neither overbought nor oversold. The STOCH value of 83.72 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PRCT.
PROCEPT BioRobotics Risk Analysis
PROCEPT BioRobotics disclosed 77 risk factors in its most recent earnings report. PROCEPT BioRobotics reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
3 New RisksPROCEPT BioRobotics Peers Comparison
Overall Rating
MDT81Outperform
BSX64Neutral- PRCT62Neutral
CNMD53Neutral
SSII52Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| MDT | 81Outperform | $129.98B | 24.77 | 10.60% | 2.83% | 9.77% | 12.28% |
| BSX | 64Neutral | $65.41B | 18.67 | 13.87% | ― | 8.88% | 25.77% |
| PRCT | 62Neutral | $1.34B | -11.55 | -33.23% | ― | 17.47% | -31.69% |
| CNMD | 53Neutral | $1.51B | 20.84 | 7.07% | ― | 1.93% | 16.93% |
| SSII | 52Neutral | $302.72M | -20.32 | -26.77% | ― | 89.98% | -0.32% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| PRCT | Procept Biorobotics Corp. | 23.51 | -6.18 | -20.82% | |
| BSX | Boston Scientific | 44.20 | -58.49 | -56.96% | |
| CNMD | Conmed Corporation | 50.48 | 8.44 | 20.08% | |
| MDT | Medtronic | 100.99 | 8.20 | 8.83% | |
| SSII | Ss Innovations International, Inc | 1.32 | -4.90 | -78.78% |
PROCEPT BioRobotics Corporate Events
PROCEPT BioRobotics Adds Esteemed Surgeon to Board
PositiveOn October 2, 2026, PROCEPT BioRobotics expanded its board of directors from nine to ten members and appointed cardiac surgeon Dr. Michael Mack as a Class II independent director, with a term running until the 2029 annual meeting of stockholders. The...
PROCEPT BioRobotics Extends Term Loan Maturity Agreement
PositiveOn September 23, 2026, PROCEPT BioRobotics Corporation amended its Loan and Security Agreement with Canadian Imperial Bank of Commerce, marking the third modification to the financing arrangement originally executed in October 2022. The latest amendm...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 05, 2026